Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target

Nuclear Medicine and Biology

Volumn 39, Issue 8, 2012, Pages 1105-1116

  Lee, Jae Hak ^a   Peters, Olaf ^b   Lehmann, Lutz ^b   Dence, Carmen S ^c   Sharp, Terry L ^c   Carlson, Kathryn E ^a   Zhou, Dong ^c   Jeyakumar, M ^a   Welch, Michael J ^c   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BAYER PHARMA AG   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

8 vinylestradiol; Breast cancer; ERB 041; Estradiol; Estrogen receptor beta

Indexed keywords

8BETA (2 FLUOROETHYL)ESTRADIOL F 18; BR 041; BR 041 BR 76; BROMINE 76; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR BINDING; TARGET ORGAN;

ANIMALS; CHEMISTRY TECHNIQUES, SYNTHETIC; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; LIGANDS; MICE; NITRILES; POSITRON-EMISSION TOMOGRAPHY; RATS; SUBSTRATE SPECIFICITY; TRIAZOLES;

EID: 84867855209     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.05.011     Document Type: Article

References (79)

1. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930.
2. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49-53.
3. Harris H.A. The unexpected science of estrogen receptor-beta selective agonists: a new class of anti-inflammatory agents?. Nucl Recept Signal 2006, 4:e012.
4. Pettersson K., Gustafsson J.A. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001, 63:165-192.
5. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., et al. Mechanisms of estrogen action. Physiol Rev 2001, 81:1535-1565.
6. Koehler K.F., Helguero L.A., Haldosen L.A., Warner M., Gustafsson J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 2005, 26:465-478.
7. Minutolo F., Macchia M., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 2011, 31:364-442.
8. Nilsson S., Koehler K.F., Gustafsson J.A. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011, 10:778-792.
9. Harris H.A. Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol 2007, 21:1-13.
10. Hewitt S.C., Harrell J.C., Korach K.S. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005, 67:285-308.
11. Harris H.A., Katzenellenbogen J.A., Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002, 143:4172-4177.
12. Meyers M.J., Sun J., Carlson K.E., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem 1999, 42:2456-2468.
13. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001, 44:4230-4251.
14. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 2000, 43:4934-4947.
15. Stauffer S.R., Huang Y.R., Aron Z.D., Coletta C.J., Sun J., Katzenellenbogen B.S., et al. Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists. Bioorg Med Chem 2001, 9:151-161.
16. Stauffer S.R., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Acyclic amides as estrogen receptor ligands: synthesis, binding, activity and receptor interaction. Bioorg Med Chem 2000, 8:1293-1316.
17. Fink B.E., Mortensen D.S., Stauffer S.R., Aron Z.D., Katzenellenbogen J.A. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol 1999, 6:205-219.
18. Ghosh U., Ganessunker D., Sattigeri V.J., Carlson K.E., Mortensen D.J., Katzenellenbogen B.S., et al. Estrogenic diazenes: heterocyclic non-steroidal estrogens of unusual structure with selectivity for estrogen receptor subtypes. Bioorg Med Chem 2003, 11:629-657.
19. Mortensen D.S., Rodriguez A.L., Carlson K.E., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor alpha. J Med Chem 2001, 44:3838-3848.
20. Mortensen D.S., Rodriguez A.L., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Furans with basic side chains: synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha. Bioorg Med Chem Lett 2001, 11:2521-2524.
21. Compton D.R., Sheng S., Carlson K.E., Rebacz N.A., Lee I.Y., Katzenellenbogen B.S., et al. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem 2004, 47:5872-5893.
22. De Angelis M., Stossi F., Carlson K.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Indazole estrogens: highly selective ligands for the estrogen receptor beta. J Med Chem 2005, 48:1132-1144.
23. De Angelis M., Stossi F., Waibel M., Katzenellenbogen B.S., Katzenellenbogen J.A. Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites. Bioorg Med Chem 2005, 13:6529-6542.
24. Zhou H.B., Comninos J.S., Stossi F., Katzenellenbogen B.S., Katzenellenbogen J.A. Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure. J Med Chem 2005, 48:7261-7274.
25. Malamas M.S., Manas E.S., McDevitt R.E., Gunawan I., Xu Z.B., Collini M.D., et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem 2004, 47:5021-5040.
26. Blizzard T.A. Selective estrogen receptor modulator medicinal chemistry at Merck. A review. Curr Top Med Chem 2008, 8:792-812.
27. Richardson T.I., Dodge J.A., Wang Y., Durbin J.D., Krishnan V., Norman B.H. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: combined A- and C-ring structure-activity relationship studies. Bioorg Med Chem Lett 2007, 17:5563-5566.
28. Fritzemeier K.H., Hillisch A., Elger W., Kaufmann U., Kollenkirchen U., Kosemund D., et al. Biological effects of ERalpha- and ERbeta-selective estrogens. Ernst Schering Res Found Workshop 2004, 127-150.
29. Hegele-Hartung C., Siebel P., Peters O., Kosemund D., Muller G., Hillisch A., et al. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc Natl Acad Sci USA 2004, 101:5129-5134.
30. Chang E.C., Frasor J., Komm B., Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006, 147:4831-4842.
31. Lindberg M.K., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson J.A., et al. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol 2003, 17:203-208.
32. Speirs V., Carder P.J., Lane S., Dodwell D., Lansdown M.R., Hanby A.M. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 2004, 5:174-181.
33. Shaaban A.M., O'Neill P.A., Davies M.P., Sibson R., West C.R., Smith P.H., et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003, 27:1502-1512.
34. Balfe P., McCann A., McGoldrick A., McAllister K., Kennedy M., Dervan P., et al. Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 2004, 30:469-474.
35. Nakopoulou L., Lazaris A.C., Panayotopoulou E.G., Giannopoulou I., Givalos N., Markaki S., et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 2004, 57:523-528.
36. Omoto Y., Kobayashi S., Inoue S., Ogawa S., Toyama T., Yamashita H., et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 2002, 38:380-386.
37. Palmieri C., Cheng G.J., Saji S., Zelada-Hedman M., Warri A., Weihua Z., et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002, 9:1-13.
38. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537-2541.
39. Speirs V., Carder P.J., Lansdown M.R. Oestrogen receptor beta: how should we measure this?. Br J Cancer 2002, 87:687. [discussion 8-9].
40. Saji S., Hirose M., Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 2005, 56(Suppl 1):21-26.
41. Esslimani-Sahla M., Kramar A., Simony-Lafontaine J., Warner M., Gustafsson J.A., Rochefort H. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 2005, 11:3170-3174.
42. Esslimani-Sahla M., Simony-Lafontaine J., Kramar A., Lavaill R., Mollevi C., Warner M., et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004, 10:5769-5776.
43. Girault I., Andrieu C., Tozlu S., Spyratos F., Bieche I., Lidereau R. Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett 2004, 215:101-112.
44. Dimolea E., Tiniakos D.G., Vassilaros S., Goutas N., Kittas C., Alexis M.N. ERb1 contributes to breast cancer response to tamoxifen 2006, [Abstract 120].
45. Seo J.W., Comninos J.S., Chi D.Y., Kim D.W., Carlson K.E., Katzenellenbogen J.A. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential PET agents for imaging estrogen receptors in breast cancer. J Med Chem 2006, Submitted.
46. Vijaykumar D., Al-Qahtani M.H., Welch M.J., Katzenellenbogen J.A. Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand: [F-18] propyl pyrazole triol. Nucl Med Biol 2003, 30:397-404.
47. Harris H.A., Albert L.M., Leathurby Y., Malamas M.S., Mewshaw R.E., Miller C.P., et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003, 144:4241-4249.
48. Yoo J., Dence C.S., Sharp T.L., Katzenellenbogen J.A., Welch M.J. Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol. J Med Chem 2005, 48:6366-6378.
49. Zhou D., Zhou H., Jenks C.C., Lewis J.S., Katzenellenbogen J.A., Welch M.J. Bromination from the macroscopic level to the tracer radiochemical level: (76)Br radiolabeling of aromatic compounds via electrophilic substitution. Bioconjugate Chem. 2009, 20:808-816.
50. Hillisch A., Peters O., Kosemund D., Muller G., Walter A., Schneider B., et al. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 2004, 18:1599-1609.
51. Carlson K.E., Choi I., Gee A., Katzenellenbogen B.S., Katzenellenbogen J.A. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 1997, 36:14897-14905.
52. Kim D.W., Jeong H.J., Lim S.T., Sohn M.H., Katzenellenbogen J.A., Chi D.Y. Facile nucleophilic fluorination reactions using tert-alcohols as a reaction medium: significantly enhanced reactivity of alkali metal fluorides and improved selectivity. J Org Chem 2008, 73:957-962.
53. Senderoff S.G., McElvany K.D., Carlson K.E., Heiman D.F., Katzenellenbogen J.A., Welch M.J. Methodology for the synthesis and specific activity determination of 16 alpha-[77Br]-bromoestradiol-17 beta and 16 alpha-[77Br]-11 beta-methoxyestradiol-17 beta, two estrogen receptor-binding radiopharmaceuticals. Int J Appl Radiat Isot 1982, 33:545-551.
54. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., Heiman D.F., Katzenellenbogen J.A., Welch M.J. Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984, 25:1212-1221.
55. Younes M., Honma N. Estrogen receptor beta. Arch Pathol Lab Med 2011, 135:63-66.
56. Alexiadis M., Eriksson N., Jamieson S., Davis M., Drummond A.E., Chu S., et al. Nuclear receptor profiling of ovarian granulosa cell tumors. Horm Cancer 2011, 2:157-169.
57. Byers M., Kuiper G.G., Gustafsson J.A., Park-Sarge O.K. Estrogen receptor-beta mRNA expression in rat ovary: down-regulation by gonadotropins. Mol Endocrinol 1997, 11:172-182.
58. Fatum M., Gyo Y., Diana P., Laufer N., Simon A. Is estradiol mandatory for an adequate follicular and embryo development? A mouse model using aromatase inhibitor (anastrozole). J Assist Reprod Genet 2006, 23:407-412.
59. Chang E.C., Charn T.H., Park S.H., Helferich W.G., Komm B., Katzenellenbogen J.A., et al. Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol 2008, 22:1032-1043.
60. Dehdashti F., Flanagan F.L., Mortimer J.E., Katzenellenbogen J.A., Welch M.J., Siegel B.A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999, 26:51-56.
61. Dehdashti F., Mortimer J.E., Siegel B.A., Griffeth L.K., Bonasera T.J., Fusselman M.J., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995, 36:1766-1774.
62. Dehdashti F., Mortimer J.E., Trinkaus K., Naughton M.J., Ellis M., Katzenellenbogen J.A., et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009, 113:509-517.
63. Linden H.M., Kurland B.F., Peterson L.M., Schubert E.K., Gralow J.R., Specht J.M., et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011, 17:4799-4805.
64. Linden H.M., Stekhova S.A., Link J.M., Gralow J.R., Livingston R.B., Ellis G.K., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006, 24:2793-2799.
65. McGuire A.H., Dehdashti F., Siegel B.A., Lyss A.P., Brodack J.W., Mathias C.J., et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991, 32:1526-1531.
66. Mortimer J.E., Dehdashti F., Siegel B.A., Katzenellenbogen J.A., Fracasso P., Welch M.J. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996, 2:933-939.
67. Mortimer J.E., Dehdashti F., Siegel B.A., Trinkaus K., Katzenellenbogen J.A., Welch M.J. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. JClin Oncol 2001, 19:2797-2803.
68. Asgari M., Morakabati A. Estrogen receptor beta expression in prostate adenocarcinoma. Diagn Pathol 2011, 6:61.
69. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134:e48-e72.
70. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999, 140:800-804.
71. Roman-Blas J.A., Castaneda S., Cutolo M., Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor beta agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res 2010, 62:1588-1593.
72. Katzenellenbogen J.A., Heiman D.F., Carlson K.E., Lloyd J.E. In vivo and in vitro steroid receptor assays in the design of estrogen pharmaceuticals. Receptor binding radiotracers 1982, 93-126. CRC Press, Boca Raton (La). W.C. Eckelman (Ed.).
73. Shanle E.K., Hawse J.R., Xu W. Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. Biochem Pharmacol 2011, 82:1940-1949.
74. Tee M.K., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R.J., et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell 2004, 15:1262-1272.
75. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64:423-428.
76. Stender J.D., Frasor J., Komm B., Chang K.C., Kraus W.L., Katzenellenbogen B.S. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007, 21:2112-2123.
77. Jiang S.Y., Jordan V.C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992, 84:580-591.
78. Katzenellenbogen J.A., Johnson H.J., Myers H.N. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 1973, 12:4085-4092.
79. Sharp T.L., Dence C.S., Engelbach J.A., Herrero P., Gropler R.J., Welch M.J. Techniques necessary for multiple tracer quantitative small-animal imaging studies. Nucl Med Biol 2005, 32:875-884.